Global Noninvasive Cancer Diagnostics Technology Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Noninvasive Cancer Diagnostics Technology Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 87

Published Date: 17 May 2022

Category: Medical Devices & Consumables

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

The Noninvasive Cancer Diagnostics Technology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Noninvasive Cancer Diagnostics Technology market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Medical Device Manufacturing Company accounting for % of the Noninvasive Cancer Diagnostics Technology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immunoassays segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Noninvasive Cancer Diagnostics Technology include Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, and A&G Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Noninvasive Cancer Diagnostics Technology market is split by Technology and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Technology and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Technology, covers
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others

Market segment by Application, can be divided into
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others

Market segment by players, this report covers
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Noninvasive Cancer Diagnostics Technology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Noninvasive Cancer Diagnostics Technology, with revenue, gross margin and global market share of Noninvasive Cancer Diagnostics Technology from 2019 to 2022.
Chapter 3, the Noninvasive Cancer Diagnostics Technology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Technology and application, with revenue and growth rate by Technology, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Noninvasive Cancer Diagnostics Technology market forecast, by regions, technology and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Noninvasive Cancer Diagnostics Technology research findings and conclusion, appendix and data source.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Noninvasive Cancer Diagnostics Technology
1.2 Classification of Noninvasive Cancer Diagnostics Technology by Technology
1.2.1 Overview: Global Noninvasive Cancer Diagnostics Technology Market Size by Technology: 2017 Versus 2021 Versus 2028
1.2.2 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Technology in 2021
1.2.3 Immunoassays
1.2.4 Molecular Diagnostics
1.2.5 Clinical Chemistry
1.2.6 Others
1.3 Global Noninvasive Cancer Diagnostics Technology Market by Application
1.3.1 Overview: Global Noninvasive Cancer Diagnostics Technology Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Medical Device Manufacturing Company
1.3.3 Oncology Laboratories
1.3.4 Government and Private Research Institutions
1.3.5 Academic Institutions and Pharmaceutical Companies
1.3.6 Others
1.4 Global Noninvasive Cancer Diagnostics Technology Market Size & Forecast
1.5 Global Noninvasive Cancer Diagnostics Technology Market Size and Forecast by Region
1.5.1 Global Noninvasive Cancer Diagnostics Technology Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Noninvasive Cancer Diagnostics Technology Market Size by Region, (2017-2022)
1.5.3 North America Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.4 Europe Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.6 South America Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Noninvasive Cancer Diagnostics Technology Market Drivers
1.6.2 Noninvasive Cancer Diagnostics Technology Market Restraints
1.6.3 Noninvasive Cancer Diagnostics Technology Trends Analysis

2 Company Profiles
2.1 Precision Therapeutics
2.1.1 Precision Therapeutics Details
2.1.2 Precision Therapeutics Major Business
2.1.3 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Solutions
2.1.4 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Precision Therapeutics Recent Developments and Future Plans
2.2 Affymetrix Inc.
2.2.1 Affymetrix Inc. Details
2.2.2 Affymetrix Inc. Major Business
2.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.2.4 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Affymetrix Inc. Recent Developments and Future Plans
2.3 Gen-Probe Incorporated
2.3.1 Gen-Probe Incorporated Details
2.3.2 Gen-Probe Incorporated Major Business
2.3.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
2.3.4 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Gen-Probe Incorporated Recent Developments and Future Plans
2.4 AVIVA Biosciences Corporation
2.4.1 AVIVA Biosciences Corporation Details
2.4.2 AVIVA Biosciences Corporation Major Business
2.4.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
2.4.4 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 AVIVA Biosciences Corporation Recent Developments and Future Plans
2.5 A&G Pharmaceutical
2.5.1 A&G Pharmaceutical Details
2.5.2 A&G Pharmaceutical Major Business
2.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Solutions
2.5.4 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 A&G Pharmaceutical Recent Developments and Future Plans
2.6 BIOVIEW Inc.
2.6.1 BIOVIEW Inc. Details
2.6.2 BIOVIEW Inc. Major Business
2.6.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.6.4 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 BIOVIEW Inc. Recent Developments and Future Plans
2.7 Quest Diagnostics Incorporated
2.7.1 Quest Diagnostics Incorporated Details
2.7.2 Quest Diagnostics Incorporated Major Business
2.7.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
2.7.4 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Quest Diagnostics Incorporated Recent Developments and Future Plans
2.8 Digene Corporation
2.8.1 Digene Corporation Details
2.8.2 Digene Corporation Major Business
2.8.3 Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
2.8.4 Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Digene Corporation Recent Developments and Future Plans
2.9 Laboratory Corporation of America Holdings.
2.9.1 Laboratory Corporation of America Holdings. Details
2.9.2 Laboratory Corporation of America Holdings. Major Business
2.9.3 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.9.4 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Laboratory Corporation of America Holdings. Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Noninvasive Cancer Diagnostics Technology Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Noninvasive Cancer Diagnostics Technology Players Market Share in 2021
3.2.2 Top 10 Noninvasive Cancer Diagnostics Technology Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Noninvasive Cancer Diagnostics Technology Players Head Office, Products and Services Provided
3.4 Noninvasive Cancer Diagnostics Technology Mergers & Acquisitions
3.5 Noninvasive Cancer Diagnostics Technology New Entrants and Expansion Plans

4 Market Size Segment by Technology
4.1 Global Noninvasive Cancer Diagnostics Technology Revenue and Market Share by Technology (2017-2022)
4.2 Global Noninvasive Cancer Diagnostics Technology Market Forecast by Technology (2023-2028)

5 Market Size Segment by Application
5.1 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2017-2022)
5.2 Global Noninvasive Cancer Diagnostics Technology Market Forecast by Application (2023-2028)

6 North America by Country, by Technology, and by Application
6.1 North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
6.2 North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
6.3 North America Noninvasive Cancer Diagnostics Technology Market Size by Country
6.3.1 North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
6.3.2 United States Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
6.3.3 Canada Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
6.3.4 Mexico Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

7 Europe by Country, by Technology, and by Application
7.1 Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
7.2 Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
7.3 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country
7.3.1 Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
7.3.2 Germany Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.3 France Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.5 Russia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.6 Italy Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Technology, and by Application
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region
8.3.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2017-2028)
8.3.2 China Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.3 Japan Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.4 South Korea Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.5 India Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.7 Australia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

9 South America by Country, by Technology, and by Application
9.1 South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
9.2 South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
9.3 South America Noninvasive Cancer Diagnostics Technology Market Size by Country
9.3.1 South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
9.3.2 Brazil Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
9.3.3 Argentina Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Technology, and by Application
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country
10.3.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
10.3.2 Turkey Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
10.3.4 UAE Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Noninvasive Cancer Diagnostics Technology Revenue by Technology, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Noninvasive Cancer Diagnostics Technology Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Noninvasive Cancer Diagnostics Technology Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Region (2017-2022)
Table 5. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2023-2028)
Table 6. Precision Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Precision Therapeutics Major Business
Table 8. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 9. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Affymetrix Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Affymetrix Inc. Major Business
Table 12. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 13. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Gen-Probe Incorporated Corporate Information, Head Office, and Major Competitors
Table 15. Gen-Probe Incorporated Major Business
Table 16. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 17. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. AVIVA Biosciences Corporation Corporate Information, Head Office, and Major Competitors
Table 19. AVIVA Biosciences Corporation Major Business
Table 20. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 21. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. A&G Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. A&G Pharmaceutical Major Business
Table 24. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 25. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. BIOVIEW Inc. Corporate Information, Head Office, and Major Competitors
Table 27. BIOVIEW Inc. Major Business
Table 28. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 29. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Quest Diagnostics Incorporated Corporate Information, Head Office, and Major Competitors
Table 31. Quest Diagnostics Incorporated Major Business
Table 32. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 33. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Digene Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Digene Corporation Major Business
Table 36. Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 37. Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Laboratory Corporation of America Holdings. Corporate Information, Head Office, and Major Competitors
Table 39. Laboratory Corporation of America Holdings. Major Business
Table 40. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 41. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Noninvasive Cancer Diagnostics Technology by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Noninvasive Cancer Diagnostics Technology Players Head Office, Products and Services Provided
Table 46. Noninvasive Cancer Diagnostics Technology Mergers & Acquisitions in the Past Five Years
Table 47. Noninvasive Cancer Diagnostics Technology New Entrants and Expansion Plans
Table 48. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Technology (2017-2022)
Table 49. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Technology (2017-2022)
Table 50. Global Noninvasive Cancer Diagnostics Technology Revenue Forecast by Technology (2023-2028)
Table 51. Global Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022)
Table 52. Global Noninvasive Cancer Diagnostics Technology Revenue Forecast by Application (2023-2028)
Table 53. North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 54. North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 55. North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 60. Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 61. Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 66. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 67. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 72. South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 73. South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 78. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 79. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Technology Picture
Figure 2. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Technology in 2021
Figure 3. Immunoassays
Figure 4. Molecular Diagnostics
Figure 5. Clinical Chemistry
Figure 6. Others
Figure 7. Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application in 2021
Figure 8. Medical Device Manufacturing Company Picture
Figure 9. Oncology Laboratories Picture
Figure 10. Government and Private Research Institutions Picture
Figure 11. Academic Institutions and Pharmaceutical Companies Picture
Figure 12. Others Picture
Figure 13. Global Noninvasive Cancer Diagnostics Technology Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Noninvasive Cancer Diagnostics Technology Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2017-2028)
Figure 16. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region in 2021
Figure 17. North America Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Noninvasive Cancer Diagnostics Technology Market Drivers
Figure 23. Noninvasive Cancer Diagnostics Technology Market Restraints
Figure 24. Noninvasive Cancer Diagnostics Technology Market Trends
Figure 25. Precision Therapeutics Recent Developments and Future Plans
Figure 26. Affymetrix Inc. Recent Developments and Future Plans
Figure 27. Gen-Probe Incorporated Recent Developments and Future Plans
Figure 28. AVIVA Biosciences Corporation Recent Developments and Future Plans
Figure 29. A&G Pharmaceutical Recent Developments and Future Plans
Figure 30. BIOVIEW Inc. Recent Developments and Future Plans
Figure 31. Quest Diagnostics Incorporated Recent Developments and Future Plans
Figure 32. Digene Corporation Recent Developments and Future Plans
Figure 33. Laboratory Corporation of America Holdings. Recent Developments and Future Plans
Figure 34. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Players in 2021
Figure 35. Noninvasive Cancer Diagnostics Technology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Noninvasive Cancer Diagnostics Technology Revenue Market Share in 2021
Figure 37. Global Top 10 Players Noninvasive Cancer Diagnostics Technology Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Technology in 2021
Figure 40. Global Noninvasive Cancer Diagnostics Technology Market Share Forecast by Technology (2023-2028)
Figure 41. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Application in 2021
Figure 42. Global Noninvasive Cancer Diagnostics Technology Market Share Forecast by Application (2023-2028)
Figure 43. North America Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 44. North America Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 45. North America Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 46. United States Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 50. Europe Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 51. Europe Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 52. Germany Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 58. Asia-Pacific Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2017-2028)
Figure 60. China Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 67. South America Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 68. South America Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 72. Middle East and Africa Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
btl

Related Reports

shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Noninvasive Cancer Diagnostics Technology Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Noninvasive Cancer Diagnostics Technology Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 87

Published Date: 17 May 2022

Category: Medical Devices & Consumables

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

The Noninvasive Cancer Diagnostics Technology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Noninvasive Cancer Diagnostics Technology market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Medical Device Manufacturing Company accounting for % of the Noninvasive Cancer Diagnostics Technology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immunoassays segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Noninvasive Cancer Diagnostics Technology include Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, and A&G Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Noninvasive Cancer Diagnostics Technology market is split by Technology and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Technology and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Technology, covers
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others

Market segment by Application, can be divided into
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others

Market segment by players, this report covers
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Noninvasive Cancer Diagnostics Technology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Noninvasive Cancer Diagnostics Technology, with revenue, gross margin and global market share of Noninvasive Cancer Diagnostics Technology from 2019 to 2022.
Chapter 3, the Noninvasive Cancer Diagnostics Technology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Technology and application, with revenue and growth rate by Technology, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Noninvasive Cancer Diagnostics Technology market forecast, by regions, technology and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Noninvasive Cancer Diagnostics Technology research findings and conclusion, appendix and data source.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Noninvasive Cancer Diagnostics Technology
1.2 Classification of Noninvasive Cancer Diagnostics Technology by Technology
1.2.1 Overview: Global Noninvasive Cancer Diagnostics Technology Market Size by Technology: 2017 Versus 2021 Versus 2028
1.2.2 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Technology in 2021
1.2.3 Immunoassays
1.2.4 Molecular Diagnostics
1.2.5 Clinical Chemistry
1.2.6 Others
1.3 Global Noninvasive Cancer Diagnostics Technology Market by Application
1.3.1 Overview: Global Noninvasive Cancer Diagnostics Technology Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Medical Device Manufacturing Company
1.3.3 Oncology Laboratories
1.3.4 Government and Private Research Institutions
1.3.5 Academic Institutions and Pharmaceutical Companies
1.3.6 Others
1.4 Global Noninvasive Cancer Diagnostics Technology Market Size & Forecast
1.5 Global Noninvasive Cancer Diagnostics Technology Market Size and Forecast by Region
1.5.1 Global Noninvasive Cancer Diagnostics Technology Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Noninvasive Cancer Diagnostics Technology Market Size by Region, (2017-2022)
1.5.3 North America Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.4 Europe Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.6 South America Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Noninvasive Cancer Diagnostics Technology Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Noninvasive Cancer Diagnostics Technology Market Drivers
1.6.2 Noninvasive Cancer Diagnostics Technology Market Restraints
1.6.3 Noninvasive Cancer Diagnostics Technology Trends Analysis

2 Company Profiles
2.1 Precision Therapeutics
2.1.1 Precision Therapeutics Details
2.1.2 Precision Therapeutics Major Business
2.1.3 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Solutions
2.1.4 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Precision Therapeutics Recent Developments and Future Plans
2.2 Affymetrix Inc.
2.2.1 Affymetrix Inc. Details
2.2.2 Affymetrix Inc. Major Business
2.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.2.4 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Affymetrix Inc. Recent Developments and Future Plans
2.3 Gen-Probe Incorporated
2.3.1 Gen-Probe Incorporated Details
2.3.2 Gen-Probe Incorporated Major Business
2.3.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
2.3.4 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Gen-Probe Incorporated Recent Developments and Future Plans
2.4 AVIVA Biosciences Corporation
2.4.1 AVIVA Biosciences Corporation Details
2.4.2 AVIVA Biosciences Corporation Major Business
2.4.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
2.4.4 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 AVIVA Biosciences Corporation Recent Developments and Future Plans
2.5 A&G Pharmaceutical
2.5.1 A&G Pharmaceutical Details
2.5.2 A&G Pharmaceutical Major Business
2.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Solutions
2.5.4 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 A&G Pharmaceutical Recent Developments and Future Plans
2.6 BIOVIEW Inc.
2.6.1 BIOVIEW Inc. Details
2.6.2 BIOVIEW Inc. Major Business
2.6.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.6.4 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 BIOVIEW Inc. Recent Developments and Future Plans
2.7 Quest Diagnostics Incorporated
2.7.1 Quest Diagnostics Incorporated Details
2.7.2 Quest Diagnostics Incorporated Major Business
2.7.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
2.7.4 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Quest Diagnostics Incorporated Recent Developments and Future Plans
2.8 Digene Corporation
2.8.1 Digene Corporation Details
2.8.2 Digene Corporation Major Business
2.8.3 Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
2.8.4 Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Digene Corporation Recent Developments and Future Plans
2.9 Laboratory Corporation of America Holdings.
2.9.1 Laboratory Corporation of America Holdings. Details
2.9.2 Laboratory Corporation of America Holdings. Major Business
2.9.3 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Solutions
2.9.4 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Laboratory Corporation of America Holdings. Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Noninvasive Cancer Diagnostics Technology Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Noninvasive Cancer Diagnostics Technology Players Market Share in 2021
3.2.2 Top 10 Noninvasive Cancer Diagnostics Technology Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Noninvasive Cancer Diagnostics Technology Players Head Office, Products and Services Provided
3.4 Noninvasive Cancer Diagnostics Technology Mergers & Acquisitions
3.5 Noninvasive Cancer Diagnostics Technology New Entrants and Expansion Plans

4 Market Size Segment by Technology
4.1 Global Noninvasive Cancer Diagnostics Technology Revenue and Market Share by Technology (2017-2022)
4.2 Global Noninvasive Cancer Diagnostics Technology Market Forecast by Technology (2023-2028)

5 Market Size Segment by Application
5.1 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2017-2022)
5.2 Global Noninvasive Cancer Diagnostics Technology Market Forecast by Application (2023-2028)

6 North America by Country, by Technology, and by Application
6.1 North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
6.2 North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
6.3 North America Noninvasive Cancer Diagnostics Technology Market Size by Country
6.3.1 North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
6.3.2 United States Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
6.3.3 Canada Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
6.3.4 Mexico Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

7 Europe by Country, by Technology, and by Application
7.1 Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
7.2 Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
7.3 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country
7.3.1 Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
7.3.2 Germany Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.3 France Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.5 Russia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
7.3.6 Italy Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Technology, and by Application
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region
8.3.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2017-2028)
8.3.2 China Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.3 Japan Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.4 South Korea Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.5 India Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
8.3.7 Australia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

9 South America by Country, by Technology, and by Application
9.1 South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
9.2 South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
9.3 South America Noninvasive Cancer Diagnostics Technology Market Size by Country
9.3.1 South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
9.3.2 Brazil Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
9.3.3 Argentina Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Technology, and by Application
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2028)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2028)
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country
10.3.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2028)
10.3.2 Turkey Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)
10.3.4 UAE Noninvasive Cancer Diagnostics Technology Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Noninvasive Cancer Diagnostics Technology Revenue by Technology, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Noninvasive Cancer Diagnostics Technology Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Noninvasive Cancer Diagnostics Technology Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Region (2017-2022)
Table 5. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2023-2028)
Table 6. Precision Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Precision Therapeutics Major Business
Table 8. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 9. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Affymetrix Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Affymetrix Inc. Major Business
Table 12. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 13. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Gen-Probe Incorporated Corporate Information, Head Office, and Major Competitors
Table 15. Gen-Probe Incorporated Major Business
Table 16. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 17. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. AVIVA Biosciences Corporation Corporate Information, Head Office, and Major Competitors
Table 19. AVIVA Biosciences Corporation Major Business
Table 20. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 21. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. A&G Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. A&G Pharmaceutical Major Business
Table 24. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 25. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. BIOVIEW Inc. Corporate Information, Head Office, and Major Competitors
Table 27. BIOVIEW Inc. Major Business
Table 28. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 29. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Quest Diagnostics Incorporated Corporate Information, Head Office, and Major Competitors
Table 31. Quest Diagnostics Incorporated Major Business
Table 32. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 33. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Digene Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Digene Corporation Major Business
Table 36. Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 37. Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Laboratory Corporation of America Holdings. Corporate Information, Head Office, and Major Competitors
Table 39. Laboratory Corporation of America Holdings. Major Business
Table 40. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Solutions
Table 41. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Noninvasive Cancer Diagnostics Technology by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Noninvasive Cancer Diagnostics Technology Players Head Office, Products and Services Provided
Table 46. Noninvasive Cancer Diagnostics Technology Mergers & Acquisitions in the Past Five Years
Table 47. Noninvasive Cancer Diagnostics Technology New Entrants and Expansion Plans
Table 48. Global Noninvasive Cancer Diagnostics Technology Revenue (USD Million) by Technology (2017-2022)
Table 49. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Technology (2017-2022)
Table 50. Global Noninvasive Cancer Diagnostics Technology Revenue Forecast by Technology (2023-2028)
Table 51. Global Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022)
Table 52. Global Noninvasive Cancer Diagnostics Technology Revenue Forecast by Application (2023-2028)
Table 53. North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 54. North America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 55. North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 60. Europe Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 61. Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 66. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 67. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 72. South America Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 73. South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2017-2022) & (USD Million)
Table 78. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Technology (2023-2028) & (USD Million)
Table 79. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Noninvasive Cancer Diagnostics Technology Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Technology Picture
Figure 2. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Technology in 2021
Figure 3. Immunoassays
Figure 4. Molecular Diagnostics
Figure 5. Clinical Chemistry
Figure 6. Others
Figure 7. Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application in 2021
Figure 8. Medical Device Manufacturing Company Picture
Figure 9. Oncology Laboratories Picture
Figure 10. Government and Private Research Institutions Picture
Figure 11. Academic Institutions and Pharmaceutical Companies Picture
Figure 12. Others Picture
Figure 13. Global Noninvasive Cancer Diagnostics Technology Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Noninvasive Cancer Diagnostics Technology Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2017-2028)
Figure 16. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region in 2021
Figure 17. North America Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Noninvasive Cancer Diagnostics Technology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Noninvasive Cancer Diagnostics Technology Market Drivers
Figure 23. Noninvasive Cancer Diagnostics Technology Market Restraints
Figure 24. Noninvasive Cancer Diagnostics Technology Market Trends
Figure 25. Precision Therapeutics Recent Developments and Future Plans
Figure 26. Affymetrix Inc. Recent Developments and Future Plans
Figure 27. Gen-Probe Incorporated Recent Developments and Future Plans
Figure 28. AVIVA Biosciences Corporation Recent Developments and Future Plans
Figure 29. A&G Pharmaceutical Recent Developments and Future Plans
Figure 30. BIOVIEW Inc. Recent Developments and Future Plans
Figure 31. Quest Diagnostics Incorporated Recent Developments and Future Plans
Figure 32. Digene Corporation Recent Developments and Future Plans
Figure 33. Laboratory Corporation of America Holdings. Recent Developments and Future Plans
Figure 34. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Players in 2021
Figure 35. Noninvasive Cancer Diagnostics Technology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Noninvasive Cancer Diagnostics Technology Revenue Market Share in 2021
Figure 37. Global Top 10 Players Noninvasive Cancer Diagnostics Technology Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Technology in 2021
Figure 40. Global Noninvasive Cancer Diagnostics Technology Market Share Forecast by Technology (2023-2028)
Figure 41. Global Noninvasive Cancer Diagnostics Technology Revenue Share by Application in 2021
Figure 42. Global Noninvasive Cancer Diagnostics Technology Market Share Forecast by Application (2023-2028)
Figure 43. North America Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 44. North America Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 45. North America Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 46. United States Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 50. Europe Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 51. Europe Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 52. Germany Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 58. Asia-Pacific Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2017-2028)
Figure 60. China Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 67. South America Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 68. South America Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Noninvasive Cancer Diagnostics Technology Sales Market Share by Technology (2017-2028)
Figure 72. Middle East and Africa Noninvasive Cancer Diagnostics Technology Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Noninvasive Cancer Diagnostics Technology Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Noninvasive Cancer Diagnostics Technology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
btl

Related Reports

jiaGou

Add To Cart

gouMai

Buy Now